Implementation and Patient Outcomes of a Pediatric COVID-19 Monoclonal Antibody Program

被引:3
作者
Blind, Jill E. [1 ]
Sapko, Matt [1 ]
Killough, Alex [1 ]
Thornton, Hannah [1 ]
Watson, Joshua R. [2 ,3 ]
机构
[1] Nationwide Childrens Hosp, Dept Pharm, 700 Childrens Dr, Columbus, OH 43205 USA
[2] Nationwide Childrens Hosp, Ctr Clin Excellence, Dept Pediat, Columbus, OH 43205 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
关键词
bamlanivimab; casirivimab; COVID-19; pediatric; SARS-CoV-2 neutralizing antibody; sotrovimab;
D O I
10.1093/jpids/piac107
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The severity and reach of the COVID-19 pandemic drove the development of various therapeutic approaches to combat SARS-CoV-2, including several neutralizing monoclonal antibody (mAb) therapies. A January 2021 pediatric consensus statement opposed routine use and recommended individualized risk assessments when considering COVID-19 mAb therapies in children and adolescents due to limited data. This report describes the implementation of a mAb referral process and the clinical outcomes of patients who received a mAb infusion in a pediatric hospital. Methods We developed a tiered allocation system based on underlying medical conditions and incorporated it into a standardized COVID-19 mAb referral and approval process. Demographics and clinical data were collected on all patients who received mAb therapy for treatment or post-exposure prophylaxis. Data recorded included sociodemographics, qualifying underlying medical conditions, clinical manifestations of infection, and overall course of treatment and disease. Results A total of 182 patients <= 21 years old received a COVID-19 mAb infusion between November 27, 2020 and January 26, 2022. Patient age ranged from 10 months to 21 years, with a median age of 15 years. In total, 7 patients (4%) had suspected adverse reactions during the infusion, and 15 (8%) patients required a COVID-19-related visit within 30 days of the mAb infusion. Conclusions A tiered allocation process may provide the framework for the stratification and efficient distribution of mAb therapies. Future research must focus on the efficacy of these therapies in the pediatric population, standardized therapeutic prioritization, and the optimal timeframe for mAb delivery to prevent progression to severe disease. This report describes the implementation of a COVID-19 monoclonal antibody referral process and the clinical outcomes of 182 patients who received a SARS-CoV-2 neutralizing monoclonal antibody infusion at a pediatric hospital.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 20 条
[1]  
American Academy of Pediatrics and the Children's Hospital Association, 2022, CHILDR COVID 19 STAT
[2]  
Centers for Disease Control and Prevention, Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals
[3]   Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City [J].
Chao, Jerry Y. ;
Derespina, Kim R. ;
Herold, Betsy C. ;
Goldman, David L. ;
Aldrich, Margaret ;
Weingarten, Jacqueline ;
Ushay, Henry M. ;
Cabana, Michael D. ;
Medar, Shivanand S. .
JOURNAL OF PEDIATRICS, 2020, 223 :14-19
[4]   Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 [J].
Dougan, M. ;
Nirula, A. ;
Azizad, M. ;
Mocherla, B. ;
Gottlieb, R. L. ;
Chen, P. ;
Hebert, C. ;
Perry, R. ;
Boscia, J. ;
Heller, B. ;
Morris, J. ;
Crystal, C. ;
Igbinadolor, A. ;
Huhn, G. ;
Cardona, J. ;
Shawa, I ;
Kumar, P. ;
Adams, A. C. ;
Van Naarden, J. ;
Custer, K. L. ;
Durante, M. ;
Oakley, G. ;
Schade, A. E. ;
Holzer, T. R. ;
Ebert, P. J. ;
Higgs, R. E. ;
Kallewaard, N. L. ;
Sabo, J. ;
Patel, D. R. ;
Dabora, M. C. ;
Klekotka, P. ;
Shen, L. ;
Skovronsky, D. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1382-1392
[5]  
FDA, 2022, EMERGENCY USE AUTHORIZATION (EUA) OF THE JANSSEN COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) WARNING: THROMBOSIS WITH THROMBOCYTOPENIA
[6]  
FDA News Release, 2020, COR COVID 19 UPD FDA
[7]  
FDA News Release, 2021, COR COVID 19 UPD FDA
[8]   Characteristics and risk factors associated with critical illness in pediatric COVID-19 [J].
Fisler, Grace ;
Izard, Stephanie M. ;
Shah, Sareen ;
Lewis, Deirdre ;
Kainth, Mundeep K. ;
Hagmann, Stefan H. F. ;
Belfer, Joshua A. ;
Feld, Lance M. ;
Mastroianni, Fiore ;
Kvasnovsky, Charlotte L. ;
Capone, Christine A. ;
Schneider, James ;
Sweberg, Todd ;
Schleien, Charles ;
Taylor, Matthew D. .
ANNALS OF INTENSIVE CARE, 2020, 10 (01)
[9]   COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study [J].
Goetzinger, Florian ;
Santiago-Garcia, Begona ;
Noguera-Julian, Antoni ;
Lanaspa, Miguel ;
Lancella, Laura ;
Carducci, Francesca I. Calo ;
Gabrovska, Natalia ;
Velizarova, Svetlana ;
Prunk, Petra ;
Osterman, Veronika ;
Krivec, Uros ;
Lo Vecchio, Andrea ;
Shingadia, Delane ;
Soriano-Arandes, Antoni ;
Melendo, Susana ;
Lanari, Marcello ;
Pierantoni, Luca ;
Wagner, Noemie ;
L'Huillier, Arnaud G. ;
Heininger, Ulrich ;
Ritz, Nicole ;
Bandi, Srini ;
Krajcar, Nina ;
Roglic, Srdan ;
Santos, Mar ;
Christiaens, Christelle ;
Creuven, Marine ;
Buonsenso, Danilo ;
Welch, Steven B. ;
Bogyi, Matthias ;
Brinkmann, Folke ;
Tebruegge, Marc .
LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (09) :653-661
[10]   Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab [J].
Gupta, Anil ;
Gonzalez-Rojas, Yaneicy ;
Juarez, Erick ;
Casal, Manuel Crespo ;
Moya, Jaynier ;
Falci, Diego R. ;
Sarkis, Elias ;
Solis, Joel ;
Zheng, Hanzhe ;
Scott, Nicola ;
Cathcart, Andrea L. ;
Hebner, Christy M. ;
Sager, Jennifer ;
Mogalian, Erik ;
Tipple, Craig ;
Peppercorn, Amanda ;
Alexander, Elizabeth ;
Pang, Phillip S. ;
Free, Almena ;
Brinson, Cynthia ;
Aldinger, Melissa ;
Shapiro, Adrienne E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) :1941-1950